Betacellulin (BTC) is a member of the EGF ligand family that directly binds to both EGFR and HER4 and induces the growth of certain epithelial cell types. Fusion proteins composed of the terminal 48 or 50 amino acids of mature betacellulin and a binding defective form of Pseudomonas exotoxin (BTC-TX 48 and BTC-TX 50 , respectively), have been produced. BTC-TX 50 induced tyrosine phosphorylation of both EGFR and HER4, whereas BTC-TX 48 induced phosphorylation of HER4 but to a much lesser extent EGFR, indicating that the presence of two additional amino acid residues, Arg 62 and Lys 63 , contribute to full kinase activity. BTC-TX 50 was up to 300-fold more active at inhibiting protein synthesis than BTC-TX 48 on cell lines expressing EGFR, most likely due to the 4tenfold higher anity of BTC-TX 50 . MDA-MB-453 breast carcinoma cells which express HER4 but not EGFR, were not sensitive to either BTC-TX form. These data indicate that despite the ability of BTC-TX to bind and phosphorylate HER4, it was only cytotoxic to cells expressing EGFR. The inability of BTC-TX to kill cells was likely due to its failure to internalize through HER4.
Introduction
Betacellulin (BTC), a growth factor in the EGF ligand family that was originally isolated from a pancreatic b cell tumor , exists as a 32 kDa glycoprotein composed of 80 amino acids containing six characteristic cysteines. BTC binds to cells expressing EGFR with a Kd of 0.5 nM, and was found to be mitogenic to a variety of cell types Watanabe et al., 1994; Seno et al., 1996) . BTC was found to bind to MDA-MB-453 cells which lack EGFR, indicating that another receptor was involved (Watanabe et al., 1994) . Subsequently, BTC was shown to directly bind HER4 (Riese et al., 1996a; Riese et al., 1996b) and have distinct signaling properties in comparison with other EGF-like ligands (Riese et al., 1996a; Beerli and Hynes, 1996; GrausPorta et al., 1997) . Human and mouse BTC are 79% homologous at the amino acid level and expression has been observed in a number of normal tissues including kidney and liver .
A variety of fusion toxins composed of EGF-like ligands and binding defective forms of Pseudomonas toxin and Diphtheria toxin have been produced (Siegall et al., 1989 (Siegall et al., , 1995 . Shaw et al., 1991; Mesri et al., 1994) . These fusion toxins have been utilized as anticancer agents both preclinically and in the clinic (LeMaistre et al., 1994; Kreitman and Pastan, 1994; Goldberg et al., 1995; Pai and Pastan, 1994) . They have also been instructive in deciphering the interactions of EGF-like ligands with speci®c HER family members and their biological consequences. One such fusion toxin, composed of heregulin b2 and PE40, a genetically engineered variant of Pseudomonas exotoxin that is devoid of its native binding domain, was found to bind cells that express HER3 or HER4 but to only kill cells that express HER4 (Siegall et al., 1995) . This suggested that heregulin (HRG) had a dierent fate following binding to HER3 and HER4 speci®cally relating to its internalization ability.
The purpose of this work was twofold, (1) to evaluate whether BTC-toxin fusion proteins would serve as potent cell killing agents for consideration in antitumor studies; and (2) to determine whether speci®c amino acids in the N-terminal domain of BTC in¯uence the binding and subsequent activity of the fusion toxin towards cells expressing EGFR and HER4. Previous studies have demonstrated that substitution of 5 amino acids located N-terminal to the ®rst cysteine of EGF, with that of HRG, confers speci®city to either HER3 or HER4 (Barbacci et al., 1995) . Analysis of BTC in this region revealed the presence of basic residues at positions 76 and 77 in relationship to the ®rst cysteine, that were not found in either EGF or HRG. To investigate whether the addition of these residues aected the activity of BTC-toxin fusion proteins, two chimeric molecules composed of the terminal 48 or 50 amino acids comprising the EGF-like domain of BTC and PE40, BTC-TX 48 and BTC-TX 50 , were constructed, expressed and puri®ed to near homogeneity. Both fusion toxins were evaluated for their ability to inhibit protein synthesis in tumor cell lines displaying EGFR and HER4, whether alone or co-expressed. Binding, phosphorylation, and internalization of BTC-TX was investigated on cells expressing EGFR or HER4.
Results

Construction, expression, and puri®cation of BTC-TX forms
The expression plasmids pSE 8.10 and pSE 8.11, encoding the 48 and 50 amino acid forms of BTC fused to PE40 under control of the IPTG inducible T7 promoter, were constructed, expressed, and the protein refolded as described in Materials and methods. The genetic constructs are depicted schematically in Figure  1 . After chromatography, the fractions corresponding to BTC-TX 48 and BTC-TX 50 were determined by SDS ± PAGE (Figure 2 ). The similar migration pattern of the two BTC-TX forms under non-reduced and reduced conditions shows their monomeric nature and their 495% level of purity as determined by analytical size exclusion chromatography (data not shown). The ®nal yield of BTC-TX was 1.5 ± 4 mg per liter of starting bacterial culture.
Receptor tyrosine phosphorylation
The two forms of BTC-TX were then investigated for their ability to signal through EGFR and HER4 by receptor tyrosine phosphorylation analysis. Extracts from NIH3T3 cells expressing either no HER family members (3T3/neo), EGFR (3T3/EGFR), or HER4 (3T3/HER4) were analysed by anti-phosphotyrosine immunoblots following exposure to BTC-TX 48 or BTC-TX 50 . BTC-TX 48 weakly induced tyrosine phosphorylation in 3T3/EGFR and 3T3/ HER4 cells (Figure 3 ). BTC-TX 50 induced tyrosine phosphorylation in both 3T3/EGFR and 3T3/HER4 cells. Neither BTC-TX form induced tyrosine phosphorylation of the parental 3T3 cells (3T3/ neo). These data show that the two additional amino acids (Arg 62 and Lys 63 ) present in BTC-TX 50 are integral for the ability of BTC to signal through EGFR and HER4.
Cytotoxicity of BTC-TX against tumor cells
The cytotoxicity of the two BTC-TX forms was determined against a variety of human tumor cell lines. Both molecules were cytotoxic with EC 50 values ranging from 9 ± 150 ng/ml for BTC-TX 48 and 0.03 ± 15 ng/ml for BTC-TX 50 ( Figure 4 , Table 1 ). BTC-TX 50 was 37-fold more cytotoxic than BTC-TX 48 against the ovarian carcinoma SKOV3 (Figure 4a ), tenfold more active against the breast carcinoma MCF-7 (Figure 4b ), and ®vefold more active versus the breast carcinoma ZR-75-1 (Figure 4c) , with >85% inhibition of protein synthesis observed. Alternatively, the breast carcinoma line MDA-MB-453 was not sensitive to the either BTC-TX form (Figure 4d ).
Correlation of receptor expression and cytotoxicity
To determine the relationship between sensitivity towards BTC-TX forms and expression of HER family members, levels of the two receptors to which BTC binds, EGFR and HER4, were determined for each cell line tested. Image analysis using speci®c mAbs was performed to quantitate relative receptor expression. Along with the four lines tested in Figure 4 , three additional cell lines, L2987 (lung carcinoma), KB (epidermoid carcinoma), and Ramos (non-Hodgkin's lymphoma), were evaluated for BTC-TX 48 and BTC-TX 50 sensitivity, and relative expression of EGFR and HER4.
Cells that express EGFR were sensitive to both BTC-TX 48 and BTC-TX 50 (Table 1) . Alternatively, cells that do not express EGFR, speci®cally MDA-MB-453 and Ramos, were not sensitive to either BTC-TX form. Interestingly, MDA-MB-453 cells, which express HER4, were not sensitive to either BTC-TX form. Expression of EGFR alone, as was the case for both L2987 and SKOV3, was sucient to impart sensitivity towards both BTC-TX forms. The sensitive cell lines, MCF-7 and KB, express both EGFR and HER4. In all cases, BTC-TX 50 was more cytotoxic than was BTC-TX 48 (Table 1) . Taken together, these data indicate that EGFR, and not HER4 expression, is essential to render cells sensitive to either BTC-TX form. Competitive cytotoxicity studies
Having shown that the expression of HER4 was not sucient to render MDA-MB-453 cells sensitive to either BTC-TX form, it was next of interest to determine whether HER4 expression contributed to sensitivity in a cell displaying both EGFR and HER4. Heterodimer complexes composed of EGFR and HER4 have been shown to exist and elicit a biological response (Cohen et al., 1996) . Using ZR-75-1 breast carcinoma cells, ligand competition experiments were performed. These cells were chosen since they express low amounts of both receptors and, as such, would provide for the best chance to observe competition upon addition of excess ligand to the cytotoxicity assay. The co-incubation of 1 mg/ml of either BTC (which binds to EGFR and HER4) or EGF (which binds to EGFR) completely blocked the cytotoxic activity of BTC-TX 50 (100 ng/ml) in a 24 h assay ( Figure 5 ). Alternatively, co-incubation with HRG (which binds to HER3 and HER4) did not aect the cytotoxic activity of BTC-TX 50 in comparison with the fusion toxin alone. Similar results were also obtained with BTC-TX 48 (data not shown). These data indicate that BTC-TX cytotoxicity is mediated through EGFR and not through HER4.
Receptor binding studies
To determine if the dierence in cytotoxicity between BTC-TX 48 and BTC-TX 50 was due to relative receptor binding anity, Scatchard analysis was performed. Transfected NIH3T3 cell lines expressing either EGFR or HER4 were chosen for the binding studies (Zhang et al., 1996) . The binding anity of BTC-TX 48 was determined to be 2.7 nM on 3T3/EGFR (Figure 6a ) and 4.8 nM on 3T3/HER4 (Figure 6b ). For BTC-TX 50 , the anity was 0.1 nM (Figure 6c ) and 0.5 nM (Figure  6d ), respectively. These data indicate that BTC-TX 48 binds up to 20-fold less well than BTC-TX 50 and may explain the dierence in the potency of the two molecules.
Internalization studies
Although able to bind HER4, both BTC-TX forms were unable to kill cells expressing HER4 in the absence of EGFR. In addition to binding, internalization is a requisite for fusion-toxin mediated cytotoxicity. Thus, the lack of cytotoxicity may be attributed to the absence of BTC-TX internalization. To address this issue, iodinated BTC-TX forms were incubated with cells for 3 h at 48C, then 1 h at 378C, and the level of internalized radioactivity determined. Neither BTC-TX form showed appreciable internalization into MDA-MB-453 cells which express HER4 but not EGFR (Figure 7) . Alternatively, both BTC-TX 48 and BTC-TX 50 internalized into SKOV3 cells which express EGFR but not HER4. These results suggest that the lack of cytotoxic activity of BTC-TX 48 and BTC-TX 50 towards cells expressing HER4 in the absence of EGFR is likely due to failure of ligand internalization.
Discussion
We have constructed, expressed, and puri®ed two ligand-toxin fusion proteins composed of the terminal 48 or 50 amino acids from the EGF-like domain of BTC genetically fused to a binding de®cient form of Pseudomonas exotoxin A, PE40. The BTC-TX proteins were isolated from inclusion bodies, denatured, refolded, and puri®ed to near homogeneity using ionexchange and sizing chromatography. These molecules, BTC-TX 48 and BTC-TX 50 , were cytotoxic towards various human tumor cells with EC 50 values of 0.1 ± 150 ng/ml. In analysing the cell lines for receptor expression it became apparent that EGFR was required for the cytotoxic activity and HER4 was not. This was supported by the observation that addition of excess EGF or BTC competed for the cytotoxic activity of BTC-TX. Alternatively, excess HRG which binds to HER3 and HER4, was unable to compete for cytotoxic activity with BTC-TX. This suggested that the expression of HER4 on cells that also express EGFR is not likely to contribute to the sensitivity to BTC-TX. Thus, EGFR but not HER4 was required for cell killing by the two BTC-TX fusion proteins. Whether the ratio of EGFR to HER4 expression in any given target cell impacts the sensitivity to BTC-TX could not be ruled out given the present data.
A fusion protein composed of HRG b2 and PE40 (HAR-TX b2) was previously shown to kill cells expressing HER4, including MDA-MB-453, but not cells expressing HER3 without HER4 (LeMaistre et al., 1994) . Thus, HER4 is capable of internalizing a targeted ligand toxin resulting in cell death. Conversely, the data presented here show that despite the direct binding to HER4, MDA-MB-453 cells which express HER4 and not EGFR, are resistant to BTC-TX-mediated cell killing. Further analysis indicated that both BTC-TX forms failed to appreciably internalize through HER4 (Figure 7 ). This is consistent with previous work in which analysis of chimeric EGF receptors expressed in NIH3T3 cells identi®ed 
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The relative levels of cell surface receptor expression was quantitated using dual color microscope-based image analysis. EC 50 is the amount of fusion protein required to inhibit 50% of the protein synthesis. 1.0 relative amount= 10 0000 sum of optical density. Nondetectable levels indicated as Ð Figure 5 Competitive cytotoxicity assay. ZR-75-1 was treated with BTC-TX 50 (at 100 ng/ml) in the presence or absence of the indicated ligands at 1 mg/ml. The data represent the mean of triplicates EGFR as the only HER family member that was eciently internalized in response to ligand (Baulida et al., 1996) . It still remains to be investigated why two dierent ligand-toxin fusion proteins (BTC-TX 50 and HAR-TX b2), each able to bind the same receptor, are internalized dierently.
In preliminary assays, the binding of BTC-TX 48 to EGFR and HER4 was reduced by 10 ± 20-fold in comparison with that of BTC-TX 50 . Since the binding anity of BTC-TX 50 to EGFR was identical to that reported for the native ligand (Watanabe et al., 1994) , the arginine and lysine at the amino terminus that were not present in BTC-TX 48 play an important role in its binding activity to EGFR and HER4.
The potential of utilizing an EGF-like ligand with dual speci®city is intriguing since most cancers express multiple receptors. The intent of selecting BTC was to determine what eect the dual targeting of EGFR and 
Materials and methods
Reagents and cell lines
Recombinant human BTC and EGF were purchased from R&D Systems (Minneapolis, MN). Heregulin b2-Ig (Colouscou et al., 1995) , referred to as HRG, was produced at Bristol-Myers Squibb Seattle, WA. Breast carcinoma cell lines MDA-MB-453, MCF-7, and ZR-75-1, epidermoid carcinoma lines A431 and KB, ovarian carcinoma line SKOV3, the mouse ®broblast line 3T3, and Ramos B-lymphoma cells were purchased from ATCC (Rockville, MD). H3396 and L2987 were established at Bristol-Myers Squibb Seattle, WA. H3396, L2987, A431, and MCF-7 were cultured in IMDM supplemented with 10% fetal bovine serum (FBS). SKOV3 was cultured in McCoy's 5a supplemented with 10% FBS. ZR-75-1 and Ramos were grown in RPMI supplemented with 10% FBS. MDA-MB-453 was grown in DMEM supplemented with 10% FBS and 0.5% non-essential amino acids. [ 3 H]leucine was purchased from Amersham (Arlington Heights, IL). Qsepharose was purchased from Pharmacia (Uppsula, Sweden). TSK sizing chromotography columns were purchased from Toso Haas (Montgomeryville, PA).
Construction of BTC-TX expression plasmids
A cDNA sequence encoding mature BTC was PCR ampli®ed from reverse transcribed mRNA isolated from the cell line MCF-7 and subcloned into pPL-lambda (Pharmacia-LKB Biotechnology) resulting in pLBTCTaq. A second PCR step was utilized to amplify a DNA segment corresponding to the terminal 48 amino acids of BTC (residues 64 ± 111; Sasada et al., 1993) and incorporating an NdeI site upstream of and including a methionine prior to BTC residue 64 and a Hind III site downstream of the tyrosine at residue 111. The resulting 174 base pair fragment was digested with NdeI and Hind III and cloned into pBW 7.0 (Friedman et al., 1993) that had been digested with the same enzymes to remove sequences encoding BR96 sFv. The resulting expression vector encoding BTC-TX 48 (pSE 8.10) contained BTC (48 amino acid form) and PE40 under control of the T7 promoter.
The expression plasmid encoding BTC-TX 50 was prepared by the same method as used for BTC-TX 48 except using oligonucleotides encoding two additional amino acids, Arg and Lys, corresponding to residues 62 and 63 of native BTC . The resulting expression construct (pSE 8.11) encodes the terminal 50 residues of BTC directly fused to PE40. Both constructs were con®rmed by DNA sequence analysis.
Expression and isolation of recombinant protein
The BTC-TX expression plasmids (pSE 8.10 and pSE 8.11) were transformed into E. coli BL21 (lDE3) and cultured in T broth containing 100 mg/ml of ampicillin at 378C until A 650 =1.0. Following a 90 min induction with 1 mM isopropyl 1-thio-b-D-galactopyranoside, the cells were harvested by centrifugation, and the pellet resuspended in ice cold sucrose buer (30 mM sucrose, 50 mM Tris-HCl, pH 8.0, 1 mM EDTA), incubated on ice for 10 min, and centrifuged. The pellet was resuspended in ice-cold H 2 O, held on ice for 10 min, and centrifuged. The resulting spheroplast pellet was resuspended in TE (50 mM Tris-HCl (pH 7.4), 1 mM EDTA) with 4% tergitol (w/v), and 5 mg/ ml lysozyme. This was incubated on ice for 10 min and centrifuged. The resulting pellet was washed from 1 ± 3 times in TE and the ®nal pellet of inclusion bodies was denatured for 60 min at 48C in 7 M guanidine hydrochloride, 30 mM Tris-HCl pH 7.0, 1 mM EDTA with agitation. Renaturation was done by addition of denatured protein into phosphate buered saline supplemented with 0.4 M L-arginine at 100 ± 150 mg/ml, and stirred overnight at 48C. This solution was extensively dialyzed against 20 mM Tris-HCl (pH 7.4) and 1 mM EDTA, ®ltered and applied to a Q-sepharose column. The BTC-TX fusion proteins were eluted with a linear salt gradient of 0 ± 1 M NaCl in 50 mM Tris-HCl (pH 7.4) and 1 mM EDTA. The fusion proteins eluted at an NaCl concentration of 0.3 ± 0.4 M and were pooled and further puri®ed using sizeexclusion chromatography (TSK-3000, TosoHaas, Philadelphia, PA). Fractions containing BTC-TX with a purity 495% as determined by Coomassie blue staining in nonreducing SDS ± PAGE were used in assays.
Phosphotyrosine assays
3T3 cells expressing no HER family members, EGFR, or HER4 (1610 6 cells) were stimulated with the indicated ligand (200 ng/ml) for 5 min at room temperature. Cells were extracted in lysis buer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate, 1 mM sodium orthovanadate) at 48C. Insoluble material was pelleted for 30 s at 10 000 g, and samples were analysed by SDS-polyacrylamide gel electrophoresis and Western blot using antiphosphotyrosine antibodies (PY20, Upstate Biotechnology, Lake Placid, NY) followed by 125 I-labeled sheep anti-mouse IgG, Fab' 2 (Dupont NEN).
Cytotoxicity assays
Cytotoxicity assays were performed as previously described (Siegall et al., 1994) . Brie¯y, tumor cells (10 5 cells/ml) were cultured in 96-well format (0.1 ml/well) and incubated at 378C for 16 h. Cells were incubated with dilutions of BTC-TX 48 or BTX-TX 50 for 20 h at 378C in quadruplicate. The cells were pulsed with [ 3 H]leucine (1 mCi/well) for an additional 4 h at 378C, lysed by freeze-thawing, and harvested using a cell harvester (Tomtec, Orange, CT). Incorporation of [ 3 H]leucine into cellular protein was determined using an LKB Beta-Plate liquid scintillation counter. Competitive cytotoxicity assays were done by coincubation of either BTC, EGF, or HRG at 1 mg/ml, and BTC-TX (100 ng/ml) on ZR-75-1 cells.
Expression of EGFR and HER4
Cells were stained for HER4 surface receptor expression as previously described (Siegall et al., 1995) . EGFR levels were determined by the alkaline phosphatase technique using an antibody to EGFR (NCL-EGFR 113; Vector Laboratories, Burlingame, CA). Image analysis was performed as previously described (Bacus et al., 1993) .
I-BTC binding experiments
BTC-TX 48 and BTC-TX 50 (50 ± 500 mg) was labeled with IODO-BEADS (Pierce, Rockford, IL) in phosphatebuered saline for 15 min at room temperature, and were puri®ed through PD10 (Pharmacia, Uppsala, Sweden) chromatography. The speci®c activity of the 125 I-BTC-TX 50 was determined to be 1.5 mCi/mg and the speci®c activity of the 125 I-BTC-TX 48 was 5.1 mCi/mg. Adherent 3T3/neo, 3T3/EGFR or 3T3/HER4 cells were removed from¯asks by incubation for 10 min at 378C with 1 mM EDTA in PBS. Receptor binding reactions were performed in triplicate at 48C for 16 h with agitation using 2610 5 cells per 100 ml reaction volumes containing 0.11 ± 14 nM 125 I-BTC-TX 48 or BTC-TX 50 in the presence or absence of unlabeled BTC-TX (200-fold excess) to determine nonspeci®c binding. Cell-bound 125 I-BTC-TX was separated from unbound by centrifugation through a 50 : 50 mixture of dibutylphthalate and dioctylphthalate at 48C and the radioactivity present in the cell pellet was determined using a g-counter. Alternatively, nonspeci®c binding was determined on parental 3T3 cells. Results obtained by both methods were identical. Scatchard analysis was then performed.
Internalization assays
Internalization assays were performed as previously described (Francisco et al., 1996) . Brie¯y, adherent cells were detached with EDTA and then incubated with 10 nM radiolabeled BTC-TX in culture media for 3 h on ice. The cells were then moved to 378C and incubated for 60 min. Membrane bound BTC-TX was removed with stripping buer (100 mM NaCl, 50 mM glycine, pH 3.0), the samples were centrifuged, the supernatant was removed, and the remaining counts were measured in a gamma counter. Counts shown represent those present at 60 min minus background counts present at 0 min.
